The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Tissue and liquid biopsy concordance in detecting EGFR mutations in NSCLC
Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, discusses the utility of liquid biopsy for detecting EGFR mutations in stage III non-small cell lung cancer (NSCLC) based on a retrospective study. The study found a high concordance rate between liquid and tissue biopsy, with liquid showing high specificity but lower sensitivity. Liquid biopsy may yield inconclusive results, necessitating tissue biopsy for confirmation in negative cases. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
